All

MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation
23 March 2026

MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more
Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
11 February 2026

Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive...

Read more
Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
10 February 2026

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

Kainova Therapeutics (“the Company”), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful first close...

Read more
Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors
29 January 2026

Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies that induce a fast and potent expansion of...

Read more
ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate
21 January 2026

ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate

ErVimmune, a biotechnology company developing next-generation therapeutic vaccines targeting new families of ‘unconventional’ tumor antigens derived from human endogenous...

Read more
MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis
20 January 2026

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in...

Read more
The Sanctuary Group raises €5 million to roll out its sports studios across France
12 January 2026

The Sanctuary Group raises €5 million to roll out its sports studios across France

Specializing in fitness studios, French startup The Sanctuary Group has announced that it has raised €4.7 million in funding. This will enable it to accelerate the rollout of...

Read more
SkillCorner Secures $60M Growth Investment to Accelerate Global Sports Data Innovation
17 December 2025

SkillCorner Secures $60M Growth Investment to Accelerate Global Sports Data Innovation

SkillCorner is pleased to announce a $60 million growth investment from Silversmith Capital Partners, marking an important step forward in our mission to deliver world-leading...

Read more
Vertero Establishes Scientific Advisory Board to Advance Innovation in Neurodegenerative Diseases
10 December 2025

Vertero Establishes Scientific Advisory Board to Advance Innovation in Neurodegenerative Diseases

Vertero Therapeutics, a clinical-stage biotechnology company breaking barriers in neurodegenerative disease treatment, today announced the appointment of five globally...

Read more